Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery

Biomaterials

Volumn 35, Issue 5, 2014, Pages 1735-1743

  Thambi, Thavasyappan ^a   Deepagan, V G ^a   Yoon, Hong Yeol ^a,b   Han, Hwa Seung ^a   Kim, Seol Hee ^a   Son, Soyoung ^a   Jo, Dong Gyu ^a   Ahn, Cheol Hee ^c   Suh, Yung Doug ^a,d   Kim, Kwangmeyung ^b   Chan Kwon, Ick ^b   Lee, Doo Sung ^a   Park, Jae Hyung ^a,d  

^a Sungkyunkwan University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Seoul National University   (South Korea)

^d Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

2 Nitroimidazole; Bioreduction; Drug delivery; Hypoxia; Nanoparticles

Indexed keywords

2-NITROIMIDAZOLE; BIO REDUCTIONS; HYPOXIA; MICROSCOPIC OBSERVATIONS; PHYSIOLOGICAL CONDITION; POLYMERIC NANOPARTICLES; SELF ASSEMBLED NANOPARTICLES; TUMOR-TARGETED DRUG DELIVERIES;

CYTOTOXICITY; DRUG DELIVERY; TUMORS;

NANOPARTICLES;

2 NITROIMIDAZOLE DERIVATIVE; CARBOXYMETHYLDEXTRAN; DOXORUBICIN; HYPOXIA RESPONSIVE NANOPARTICLE; NANOCARRIER; NANOCONJUGATE; NANOPARTICLE; POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TISSUE; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; HYDROPHOBICITY; HYPOXIA; HYPOXIC CELL; IN VIVO STUDY; MICROSCOPY; MOUSE; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SUSTAINED DRUG RELEASE; TISSUE DISTRIBUTION;

2-NITROIMIDAZOLE; BIOREDUCTION; DRUG DELIVERY; HYPOXIA; NANOPARTICLES;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL HYPOXIA; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICE; NANOPARTICLES; NEOPLASMS; POLYMERS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890175659     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.11.022     Document Type: Article

References (38)

1. Harris A.L. Hypoxia- a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
2. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4:437-447.
3. Takasawa M., Moustafa R.R., Baron J.-C. Applications of nitroimidazole invivo hypoxia imaging in ischemic stroke. Stroke 2008, 39:1629-1637.
4. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011, 11:393-410.
5. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
6. Kiyose K., Hanaoka K., Oushiki D., Nakamura T., Kajimura M., Suematsu M., et al. Hypoxia-Sensitive fluorescent probes for invivo real-time fluorescence imaging of acute ischemia. JAm Chem Soc 2010, 132:15846-15848.
7. Cui L., Zhong Y., Zhu W., Xu Y., Du Q., Wang X., et al. Anew prodrug-derived ratiometric fluorescent probe for hypoxia: high selectivity of nitroreductase and imaging in tumor cell. Org Lett 2011, 13:928-931.
8. Okuda K., Okabe Y., Kadonosono T., Ueno T., Youssif B.G.M., Kizaka-Kondoh S., et al. 2-Nitroimidazole-tricarbocyanine conjugate as a near-infrared fluorescent probe for invivo imaging of tumor hypoxia. Bioconjug Chem 2012, 23:324-329.
9. Liu Y., Xu Y., Qian X., Liu J., Shen L., Li J., et al. Novel fluorescent markers for hypoxic cells of naphthalimides with two heterocyclic side chains for bioreductive binding. Bioorg Med Chem 2006, 14:2935-2941.
10. Hodgkiss R.J., Middleton R.W., Parrick J., Rami H.K., Wardman P., Wilson G.D. Bioreductive fluorescent markers for hypoxic cells: a study of 2-nitroimidazoles with 1-substituents containing fluorescent, bridgehead-nitrogen, bicyclic systems. JMed Chem 1992, 35:1920-1926.
11. Hodgkiss R.J., Jones G., Long A., Parrick J., Smith K.A., Stratford M.R.L., et al. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. Br J Cancer 1991, 63:119-125.
12. Edwards D.I. Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action. JAntimicrob Chemother 1993, 31:9-20.
13. Min K.H., Park K., Kim Y.-S., Bae S.M., Lee S., Jo H.G., et al. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. JControl Release 2008, 127:208-218.
14. Park K., Kim J.-H., Nam Y.S., Lee S., Nam H.Y., Kim K., et al. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. JControl Release 2007, 122:305-314.
15. Rai S., Paliwal R., Vyas S.P. Doxorubicin encapsulated nanocarriers for targeted delivery to estrogen responsive breast cancer. JBiomed Nanotechnol 2011, 7:121-122.
16. Jianquan F., Gang F., Xiaodan W., Fang Z., Yufei X., Shuizhu W. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles. Nanotechnology 2011, 22:455102.
17. Choi K.Y., Min K.H., Na J.H., Choi K., Kim K., Park J.H., et al. Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and invivo biodistribution. JMater Chem 2009, 19:4102-4107.
18. Shuai X., Ai H., Nasongkla N., Kim S., Gao J. Micellar carriers based on block copolymers of poly(ε-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. JControl Release 2004, 98:415-426.
19. Meng F., Zhong Z., Feijen J. Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules 2009, 10:197-209.
20. Oh K.T., Yin H., Lee E.S., Bae Y.H. Polymeric nanovehicles for anticancer drugs with triggering release mechanisms. JMater Chem 2007, 17:3987-4001.
21. Choi K.Y., Yoon H.Y., Kim J.-H., Bae S.M., Park R.-W., Kang Y.M., et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 2011, 5:8591-8599.
22. Fan N.-C., Cheng F.-Y., Ho J.-aA., Yeh C.-S. Photocontrolled targeted drug delivery: photocaged biologically active folic acid as a light-responsive tumor-targeting molecule. Angew Chem Int Ed Engl 2012, 51:8806-8810.
23. Shamay Y., Adar L., Ashkenasy G., David A. Light induced drug delivery into cancer cells. Biomaterials 2011, 32:1377-1386.
24. Liu J., Huang W., Pang Y., Huang P., Zhu X., Zhou Y., et al. Molecular self-assembly of a homopolymer: an alternative to fabricate drug-delivery platforms for cancer therapy. Angew Chem Int Ed Engl 2011, 50:9162-9166.
25. Thambi T., Yoon H.Y., Kim K., Kwon I.C., Yoo C.K., Park J.H. Bioreducible block copolymers based on Poly(Ethylene glycol) and Poly(γ-Benzyl l-Glutamate) for intracellular delivery of camptothecin. Bioconjug Chem 2011, 22:1924-1931.
26. Thambi T., Deepagan V.G., Ko H., Lee D.S., Park J.H. Bioreducible polymersomes for intracellular dual-drug delivery. JMater Chem 2012, 22:22028-22036.
27. Bae Y., Fukushima S., Harada A., Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew Chem Int Ed Engl 2003, 42:4640-4643.
28. Thambi T., Deepagan V.G., Yoo C.K., Park J.H. Synthesis and physicochemical characterization of amphiphilic block copolymers bearing acid-sensitive orthoester linkage as the drug carrier. Polymer 2011, 52:4753-4759.
29. Han S.-Y., Han H.S., Lee S.C., Kang Y.M., Kim I.-S., Park J.H. Mineralized hyaluronic acid nanoparticles as a robust drug carrier. JMater Chem 2011, 21:7996-8001.
30. Liu S.Q., Tong Y.W., Yang Y.-Y. Incorporation and invitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(d,l-lactide-co-glycolide) with varying compositions. Biomaterials 2005, 26:5064-5074.
31. Fang F., Gong C., Qian Z., Zhang X., Gou M., You C., et al. Honokiol nanoparticles in thermosensitive hydrogel: therapeutic effects on malignant pleural effusion. ACS Nano 2009, 3:4080-4088.
32. Peng J., Qi T., Liao J., Fan M., Luo F., Li H., et al. Synthesis and characterization of novel dual-responsive nanogels and their application as drug delivery systems. Nanoscale 2012, 4:2694-2704.
33. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 2004, 91:1775-1781.
34. Shahnaz G., Perera G., Sakloetsakun D., Rahmat D., Bernkop-Schnürch A. Synthesis, characterization, mucoadhesion and biocompatibility of thiolated carboxymethyl dextran-cysteine conjugate. JControl Release 2010, 144:32-38.
35. McIntosh D.P., Cooke R.J., McLachlan A.J., Daley-Yates P.T., Rowland M. Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice. JPharm Sci 1997, 86:1478-1483.
36. Zhang Y., Angelidaki I. Submersible microbial fuel cell sensor for monitoring microbial activity and BOD in groundwater: focusing on impact of anodic biofilm on sensor applicability. Biotechnol Bioeng 2011, 108:2339-2347.
37. Oh S.E., Kim J.R., Joo J.-H., Logan B.E. Effects of applied voltages and dissolved oxygen on sustained power generation by microbial fuel cells. Water Sci Technol 2009, 60:1311-1317.
38. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.